This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pradono, P. Articles by Nukiwa, T. Search for Related Content PubMed PubMed Citation Articles by Pradono, P. Articles by Nukiwa, T.

Gene Transfer of Thromboxane A₂ Synthase and Prostaglandin I₂ Synthase Antithetically Altered Tumor Angiogenesis and Tumor Growth¹

Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan

Cyclooxygenase, involved in tumor growth and angiogenesis, converts arachidonic acid to prostaglandin (PG)H₂, which is immediately converted to bioactive prostanoids including PGE₂, PGD₂, thromboxane (TX)A₂ and PGI₂. To test the hypothesis that changes in the prostanoid profile alter cancer growth, we transduced the retroviral vectors carrying TXA₂ synthase cDNA or PGI₂ synthase cDNA to colon-26 adenocarcinoma cells and subsequently inoculated each transformant to syngeneic BALB/c mice. Tumors derived from TXA₂ synthase transformants grew faster (280%, day 8, versus null-vector control; P < 0.05) and showed more abundant vasculature (204%, versus null-vector control; P < 0.01), whereas tumors from PGI₂ synthase transformants presented opposite effects. These effects by the transgenes were reversed by administration of specific inhibitors. These results suggest that the profile of downstream metabolites of cyclooxygenase in cancer cells can be a determinant for tumor development.

This article has been cited by other articles:

				X. Li and H.-H. Tai Activation of thromboxane A2 receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells Carcinogenesis, September 1, 2009; 30(9): 1606 - 1613. [Abstract] [Full Text] [PDF]

				M. D. Salvado, A. Alfranca, A. Escolano, J. Z. Haeggstrom, and J. M. Redondo COX-2 Limits Prostanoid Production in Activated HUVECs and Is a Source of PGH2 for Transcellular Metabolism to PGE2 by Tumor Cells Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1131 - 1137. [Abstract] [Full Text] [PDF]

				C. F.A. Vogel, W. Li, E. Sciullo, J. Newman, B. Hammock, J. R. Reader, J. Tuscano, and F. Matsumura Pathogenesis of Aryl Hydrocarbon Receptor-Mediated Development of Lymphoma Is Associated with Increased Cyclooxygenase-2 Expression Am. J. Pathol., November 1, 2007; 171(5): 1538 - 1548. [Abstract] [Full Text] [PDF]

				X. de Leval, T. Dassesse, J.-M. Dogne, D. Waltregny, A. Bellahcene, V. Benoit, B. Pirotte, and V. Castronovo Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1057 - 1067. [Abstract] [Full Text] [PDF]

				T. G. Neilan, D. S. Jassal, M. F. Scully, G. Chen, C. Deflandre, H. McAllister, E. Kay, S. C. Austin, E. F. Halpern, J. H. Harmey, et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression Eur. Heart J., May 2, 2006; 27(10): 1251 - 1256. [Abstract] [Full Text] [PDF]

				W. Yan and H.-H. Tai Glycogen Synthase Kinase-3 Phosphorylation, T-Cell Factor Signaling Activation, and Cell Morphology Change following Stimulation of Thromboxane Receptor {alpha} J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 267 - 274. [Abstract] [Full Text] [PDF]

				E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF]

				F. Michel, J.-S. Silvestre, L. Waeckel, S. Corda, T. Verbeuren, J. P. Vilaine, M. Clergue, M. Duriez, and B. I. Levy Thromboxane A2/Prostaglandin H2 Receptor Activation Mediates Angiotensin II-Induced Postischemic Neovascularization Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 488 - 493. [Abstract] [Full Text] [PDF]

				D Wang and R N DuBois PROSTAGLANDINS AND CANCER Gut, January 1, 2006; 55(1): 115 - 122. [Full Text] [PDF]

				O. Moussa, J. S. Yordy, H. Abol-Enein, D. Sinha, N. K. Bissada, P. V. Halushka, M. A. Ghoneim, and D. K. Watson Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer Cancer Res., December 15, 2005; 65(24): 11581 - 11587. [Abstract] [Full Text] [PDF]

				A. W. Ashton and J. A. Ware Thromboxane A2 Receptor Signaling Inhibits Vascular Endothelial Growth Factor-Induced Endothelial Cell Differentiation and Migration Circ. Res., August 20, 2004; 95(4): 372 - 379. [Abstract] [Full Text] [PDF]

				R. L. Keith, Y. E. Miller, T. M. Hudish, C. E. Girod, S. Sotto-Santiago, W. A. Franklin, R. A. Nemenoff, T. H. March, S. P. Nana-Sinkam, and M. W. Geraci Pulmonary Prostacyclin Synthase Overexpression Chemoprevents Tobacco Smoke Lung Carcinogenesis in Mice Cancer Res., August 15, 2004; 64(16): 5897 - 5904. [Abstract] [Full Text] [PDF]

				A. W. Ashton, Y. Cheng, A. Helisch, and J. A. Ware Thromboxane A2 Receptor Agonists Antagonize the Proangiogenic Effects of Fibroblast Growth Factor-2: Role of Receptor Internalization, Thrombospondin-1, and {alpha}v{beta}3 Circ. Res., April 2, 2004; 94(6): 735 - 742. [Abstract] [Full Text] [PDF]